Online inquiry

IVTScrip™ mRNA-Anti-IFNAR, Peg-IFNA2 R23(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13028MR)

This product GTTS-WQ13028MR is a type of mRNA modified with 2-Thio-UTP, which ecodes the monoclonal antibody that targets IFNAR gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
RefSeq NM_000629.3; NM_000874.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3454; 3455
UniProt ID P17181; P17181
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IFNAR, Peg-IFNA2 R23(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ13028MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6983MR IVTScrip™ mRNA-Anti-pagA, ETI-204(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ETI-204
GTTS-WQ14516MR IVTScrip™ mRNA-Anti-IL6R, SA-237(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SA-237
GTTS-WQ12415MR IVTScrip™ mRNA-Anti-CD3E, NI-0401(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA NI-0401
GTTS-WQ12243MR IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MPDL3280A
GTTS-WQ4259MR IVTScrip™ mRNA-Anti-LINGO1, BIIB-033(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BIIB-033
GTTS-WQ6306MR IVTScrip™ mRNA-Anti-TNFRSF10B, CS-1008(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CS-1008
GTTS-WQ7221MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA FMC63 scFv-G4h-28-F9Z-TpERt CAR
GTTS-WQ7643MR IVTScrip™ mRNA-Anti-TNFRSF10B, GEN-1029(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GEN-1029
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW